BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8511115)

  • 1. [Biological markers of cancer. Critical study].
    Bellet D; Bidart JM
    Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
    Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
    J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the role of established tumour markers.
    Beastall GH; Cook B; Rustin GJ; Jennings J
    Ann Clin Biochem; 1991 Jan; 28 ( Pt 1)():5-18. PubMed ID: 2024935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
    Canil CM; Tannock IF
    Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in biological markers for cancer.
    Klavins JV
    Ann Clin Lab Sci; 1983; 13(4):275-80. PubMed ID: 6194735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical relevance of tumor markers].
    Lamerz R
    Wien Klin Wochenschr; 1989 Jul; 101(14):464-72. PubMed ID: 2672606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms.
    Marcillac I; Troalen F; Bidart JM; Ghillani P; Ribrag V; Escudier B; Malassagne B; Droz JP; Lhommé C; Rougier P
    Cancer Res; 1992 Jul; 52(14):3901-7. PubMed ID: 1377600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer screening through a multi-analyte serum biomarker panel during health check-up examinations: Results from a 12-year experience.
    Wen YH; Chang PY; Hsu CM; Wang HY; Chiu CT; Lu JJ
    Clin Chim Acta; 2015 Oct; 450():273-6. PubMed ID: 26344337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Human Chorionic Gonadotropin as Tumor Marker: Biochemical and Clinical Aspects.
    Sisinni L; Landriscina M
    Adv Exp Med Biol; 2015; 867():159-76. PubMed ID: 26530366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor markers of breast cancer].
    Sławicki S; Mroczko B; Szmitkowski M
    Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical evaluation of human esophageal neoplasms and preneoplastic lesions for beta-chorionic gonadotropin, placental lactogen, alpha-fetoprotein, carcinoembryonic antigen, and nonspecific cross-reacting antigen.
    Burg-Kurland CL; Purnell DM; Combs JW; Hillman EA; Harris CC; Trump BF
    Cancer Res; 1986 Jun; 46(6):2936-43. PubMed ID: 2421889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer.
    Louhimo J; Kokkola A; Alfthan H; Stenman UH; Haglund C
    Int J Cancer; 2004 Oct; 111(6):929-33. PubMed ID: 15300805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study.
    Takahashi Y; Takeuchi T; Sakamoto J; Touge T; Mai M; Ohkura H; Kodaira S; Okajima K; Nakazato H;
    Gastric Cancer; 2003; 6(3):142-5. PubMed ID: 14520526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical application of tumour markers: a review.
    Amayo AA; Kuria JG
    East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The "false positive" tumor marker in malignant testicular tumor].
    Bussar-Maatz R; Weissbach L; Dahlmann N; Mann K
    Urologe A; 1993 May; 32(3):177-82. PubMed ID: 8511831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of tumour markers, cytogenetics.
    Lamerz R
    Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.